Summarized ScienceMar 7

🦠 Melanoma - Feb 2026

• Personalized mRNA vaccine shows durable reduction in melanoma recurrence
• HOXD13 regulates angiogenesis and immune evasion in melanoma
• Pepyrus boosts sensitivity in HLA-bound neoantigen discovery
• SITC defines consensus criteria for ICI resistance
• Vibostolimab adds no benefit over pembrolizumab alone in melanoma
• Pathologic response assessment shows high reproducibility across tumor types

https://pir.sh/RbZ1DNrajK

#Melanoma #Immunotherapy #Oncology

Melanoma Research Summary February 2026 - Summarized Science

Summary of key Melanoma publications highlighting major findings, clinical relevance, and emerging research trends.

br00t4cMar 1
'Money or malice': What's really behind Melania Trump's UN appearance Why can't it be both? #BeBest #Melanoma #SendBarron www.alternet.org/melania-trum...

'Money or malice': What's real...
'Money or malice': What's really behind Melania Trump's UN appearance

First Lady Melania Trump is leading the United Nations Security Council next week, and it's prompting some to wonder what the angle is for the Trumps to benefit. Writing for The Guardian on Saturday, columnist Arwa Mahdawi explained, "It is my working hypothesis that there are only two reasons a Tru...

Alternet.org
Summarized ScienceFeb 12

🎗️ Melanoma — Recent Research

• Long-term survival improves with neoadjuvant checkpoint blockade
• Targeted therapy benefits linked to mutation burden
• CRISPR screens and toxicity insights refine immunotherapy strategy

https://pir.sh/rk915wQanp

#Melanoma #Immunotherapy

Melanoma Research Summary January 2026 - Summarized Science

Summary of key Melanoma publications highlighting major findings, clinical relevance, and emerging research trends.

Show threadbkFeb 7
@Ann1944
#Melanoma
Show threadcancergraceJan 30

Learn what your diagnosis means, explore current treatment options—including therapies that work with your immune system—and feel more confident as you move forward.

Watch here: https://www.medlive.com/patient/show/25-12-19-nmsc-patient-session?pqat=4a9e289975ed1730a217f4e72c12e705c1c0125528017b5616565d054e17836c5430110257a4b081b968c2345170f320bb43bafc2eb8e859a60d95997afb2aea&refCode=par_soc_CancerGRACE_121925_NMSC_OD_social

#Melanoma #NonMelanoma #SkinCancer

New Ways to Treat Non-Melanoma Skin Cancer

Learn about BCC and cSCC treatments, including immunotherapy, and hear real patient stories to help guide your care and treatment choices.

Medlive.com
Scientific FrontlineJan 29
#Neoadjuvant treatment with the #immunotherapy drug pembrolizumab significantly shrinks or eliminates #tumors in patients with desmoplastic #melanoma , a rare and aggressive form of skin #cancer
#Oncology #Immunology #Dermatology #sflorg
https://www.sflorg.com/2026/01/ongy01292601.html
Immunotherapy before surgery helps shrink tumors in patients with desmoplastic melanoma

New approach spares patients from more disfiguring surgeries or additional treatments

John YatesJan 29
Boycott #Melanoma "s skin-flick! #GoldDigger #Politics
John YatesJan 26
Boycott #Melanoma "s skin-flick! #GoldDigger #Politics
Ars Technica NewsJan 22
mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say https://arstechni.ca/Ejjf #clinicaltrial #skincancer #melanoma #moderna #vaccine #Health #cancer #mRNA
mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say

The vaccines are tailor-made to target each patient's unique cancer.

Ars Technica
Yonhap Infomax NewsJan 8
Hanmi Pharmaceutical has received regulatory approval to begin a Phase 2 clinical trial of its targeted melanoma drug Belvarafenib, aiming to address unmet needs in cancer treatment with a combination therapy for patients with NRAS-mutant melanoma.
#YonhapInfomax #HanmiPharmaceutical #Belvarafenib #Melanoma #ClinicalTrial #NRASMutation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99004
Hanmi Pharmaceutical Initiates Phase 2 Clinical Trial for Melanoma Drug

Hanmi Pharmaceutical has received regulatory approval to begin a Phase 2 clinical trial of its targeted melanoma drug Belvarafenib, aiming to address unmet needs in cancer treatment with a combination therapy for patients with NRAS-mutant melanoma.

Yonhap Infomax